<em>This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game </em>

The Market Herald11-25 00:00

For years, people dreamed that science would one day create a pill to cure all ills. Today, one small pill may not cure everything, but it holds the potential to transform cognitive medicine by ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2486792724?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-25 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486792724","market":"us","top_or_hot":-1,"title":"<em>This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game </em>","media":"The Market Herald","content":"<div>\n<p>For years, people dreamed that science would one day create a pill to cure all ills. \nToday, one small pill may not cure everything, but it holds the potential to transform cognitive medicine by ...</p>\n\n<a href=\"https://themarketonline.com.au/this-biotech-stock-raised-11m-in-a-risk-off-environment-its-alzheimers-drug-could-change-the-game-2024-11-25/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title><em>This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game </em></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n<em>This biotech stock raised $11M in a risk-off environment. Its Alzheimer’s drug could change the game </em>\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-25 00:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/this-biotech-stock-raised-11m-in-a-risk-off-environment-its-alzheimers-drug-could-change-the-game-2024-11-25/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For years, people dreamed that science would one day create a pill to cure all ills. \nToday, one small pill may not cure everything, but it holds the potential to transform cognitive medicine by ...</p>\n\n<a href=\"https://themarketonline.com.au/this-biotech-stock-raised-11m-in-a-risk-off-environment-its-alzheimers-drug-could-change-the-game-2024-11-25/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XKO.AU","symbol_name":"标普/澳交所 300指数","start_time":0,"source_url":"https://themarketonline.com.au/this-biotech-stock-raised-11m-in-a-risk-off-environment-its-alzheimers-drug-could-change-the-game-2024-11-25/","article_id":"2486792724","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486792724","pubTimestamp":1732464000,"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"For years, people dreamed that science would one day create a pill to cure all ills.Today, one small pill may not cure everything, but it holds the potential to transform cognitive medicine by addressing debilitating conditions like depression and Alzheimer’s.This is the promise of Xanamem, a breakthrough from Actinogen Medical  that could improve the lives of millions in Australia and around the world.Depression and Alzheimer’s are among the most widespread mental health challenges in Australia, affecting countless individuals and families. Decades of research has highlighted a link between these conditions and cortisol—a hormone related to stress.Actinogen’s Xanamem is the first medication that can control brain tissue cortisol without affecting normal levels of cortisol needed in the rest of the body.Xanamem provides a novel approach to managing depression, known as the “black dog,” and for slowing Alzheimer’s progression.","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"XKO.AU":"标普/澳交所 300指数","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","BK7508":"医药生物股","ACW.AU":"ACTINOGEN MEDICAL LTD","XJO.AU":"标普/澳交所 200指数"},"translate_title":"<em>这只生物科技股在避险环境下筹集了1100万美元。它的阿尔茨海默氏症药物可能会改变游戏规则</em>","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACW.AU":1,"XAO.AU":0.9,"XJO.AU":0.9,"XKO.AU":0.9},"content_text":"For years, people dreamed that science would one day create a pill to cure all ills. \nToday, one small pill may not cure everything, but it holds the potential to transform cognitive medicine by addressing debilitating conditions like depression and Alzheimer’s. \nThis is the promise of Xanamem, a breakthrough from Actinogen Medical (ASX:ACW) that could improve the lives of millions in Australia and around the world.\nDepression and Alzheimer’s are among the most widespread mental health challenges in Australia, affecting countless individuals and families. Decades of research has highlighted a link between these conditions and cortisol—a hormone related to stress. \nActinogen’s Xanamem is the first medication that can control brain tissue cortisol without affecting normal levels of cortisol needed in the rest of the body. \nXanamem provides a novel approach to managing depression, known as the “black dog,” and for slowing Alzheimer’s progression.\nThe statistics underscore the need for such a solution. \nThe Australian Institute of Health and Welfare (AIHW) reports that nearly 20% of Australians have experienced depression—more than 5 million people in a population of 26.7 million. Alzheimer’s also has a profound impact; Health Direct notes that 1 in 10 Australians over 65 are affected, with this number set to rise as the population ages.\nActinogen’s clinical trial for Xanamem, now underway in Australia and the United States, is enrolling 220 patients with Alzheimer’s. In prior trials, the drug has shown promising effects in patients with Alzheimer’s and those with moderately severe depression and a promising safety profile. \nActinogen’s CEO Dr Steve Gourlay believes the simplicity of Xanamem’s once-daily oral dose is a major advantage, especially for Alzheimer’s patients and caregivers who may find infusion therapy with new antibody drugs challenging. \nData gathered so far strongly supports the theory that cortisol management could be effective for a number of serious diseases.\nActinogen recently raised $11 million, with Gourlay contributing $1 million personally, demonstrating strong confidence from leadership and investors alike. \nWith another $9 million just received from an R&D tax rebate, Actinogen has nearly $25 million on hand, ensuring operations are funded through mid-2026.\nThe breakthrough here is significant: Xanamem could reshape how we approach Alzheimer’s—and potentially reflect a “Holy Grail”, on its own or as combination therapy, that scientists have been looking for.\nDisclaimer: Actinogen contributed content for this article.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486792724"}